Updated GC-MS Systems for HRAM Sample Analysis
Thermo Fisher Scientific’s Orbitrap GC-MS systems has new capabilities in high-resolution accurate mass for laboratories performing gas chromatography mass spectrometry.
Thermo Fisher Scientific’s Orbitrap GC-MS systems have new capabilities suited to provide highly sensitive, selective, and accurate compound identification of complex samples for both research and routine laboratories performing gas chromatography mass spectrometry (GC-MS).
The brand’s Q Exactive GC system provides data for compound discovery, identification, and quantitation for comprehensive analyses. The Exactive GC system delivers sensitive, routine-grade performance in both targeted and non-targeted screening protocols. Both systems provide improved resolving power, mass accuracy, linear dynamic range, and sensitivity of Orbitrap technology.
Features now include the addition of variable electron voltage (VeV) technology for electron ionization (EI), the brand’s high-resolution accurate mass (HRAM) metabolomics library, and the TraceFinder automated compound identification. The VeV technology enables low electron voltage settings to be used during EI protocols, promoting high mass signals and providing high sensitivity for compounds prone to extensive fragmentation, according to the company.
In the HRAM metabolomics library for EI, metabolite identification is streamlined. The library includes more than 800 metabolites, and the spectra is refined and curated with the elemental composition of each EI fragment verified. New TraceFinder software features a specialized spectral deconvolution library and automated compound identification to enable identification of challenging compounds. According to the company, with the addition of Kovats retention index to the scoring index of unknowns, user confidence in compound identification is improved, specifically in relation to isomeric compounds.
Source: Thermo Fisher Scientific
Why is the PDA Pharmaceutical Microbiology Conference the Hottest Ticket in the Industry?
October 10th 2024Get a glimpse of the power and popularity behind the PDA Pharmaceutical Microbiology Conference from two planning committee members, Julia Marre, PhD (Associate Director, Scientific and Regulatory Affairs at Pocket Naloxone Corp) and Dawn Watson (Executive Director, Global Micro Quality and Sterility Assurance at Merck). This candid conversation reveals why this industry event is so influential…and always sold out! The speakers discuss what makes the PDA Pharmaceutical Microbiology Conference so vital to industry professionals, as well as how to become a part of this dynamic professional community.
Navigating Annex 1 for Early Phase Sterile Fill Finish in Clinical Supplies
November 21st 2024Stay compliant with Annex 1 for early phase sterile fill finish processes. Discover how to implement robust contamination control strategies, integrate isolator technology, and conduct integrity testing to meet stringent European Union standards. The guide provides a comprehensive look at key elements such as PUPSIT, critical zone controls, and monitoring and training for aseptic processes.
Your Ultimate Guide for CMC Testing Support for Gene and Cell Therapy
November 21st 2024Explore the complexities of gene and cell therapy development with our comprehensive guide to Chemistry, Manufacturing, and Controls (CMC) testing. Learn how our expertise ensures the safety, potency, and quality of advanced therapies, supporting your journey from product development through regulatory approval.
